Nicotinamide Riboside and Mitochondrial Metabolism
Sponsor: Helsinki University Central Hospital
Collaborators: University of Helsinki, University of Iowa, National Institute for Health and Welfare, Finland, Göteborg University
Purpose
Investigators describe a proposal where they use NR to activate dysfunctional mitochondria, in particular the SIRT/NAD+ pathway, and to rescue signs of obesity-related diseases. The investigators use a unique human study design: monozygotic twins either discordant or concordant for obesity, to examine the effects of NR on mitochondrial function in muscle, adipose tissue and metabolism of the whole body. The upcoming results are important for understanding the links between mitochondrial dysfunction and chronic metabolic diseases in humans, as well as for clarifying mechanisms of the novel nutritional therapeutic approaches.
Study Design
Open label, non randmized, placebo controlled, parallel assignment
Dose
Healthy BMI-discordant monozygotic twin pairs both treated with NR receive final dose of 1g/day. Gradually escalated by 250mg/week reaching 1g/day in one month.
Healthy monozygotic twins concordant for BMI, randomized: 1 twin NR, 1 twin placebo. Final dose for NR or placebo is 1g/day. Gradually escalated by 250mg/week reaching 1g/day in one month.
Length of Intervention
Healthy BMI-discordant monozygotic twin pairs: 4 months with full NR dose, total duration 5 months, at end of study daily dose will be decreased by 250mg/week rate.
Healthy monozygotic twins concordant for BMI- 4 months with full placebo/NR dose, total duration 5 months, at end of study daily dose will be decreased by 250mg/week rate.
Intrinsic Capacity
Vitality
Status
Completed
Condition or Disease
Obesity
Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.